Arch Therapeutics Inc (ARTH) Lifted to Hold at ValuEngine
ValuEngine upgraded shares of Arch Therapeutics Inc (NASDAQ:ARTH) from a sell rating to a hold rating in a research report released on Saturday morning.
Several other equities research analysts have also recently weighed in on the stock. Roth Capital set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a buy rating in a research report on Thursday, May 4th. Zacks Investment Research cut shares of Arch Therapeutics from a buy rating to a sell rating in a research report on Monday, May 8th. Ifs Securities reaffirmed an outperform rating on shares of Arch Therapeutics in a research report on Tuesday, July 25th. Finally, HC Wainwright set a $3.00 price objective on shares of Arch Therapeutics and gave the stock a buy rating in a research report on Monday, June 12th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Arch Therapeutics has a consensus rating of Buy and a consensus target price of $2.31.
Shares of Arch Therapeutics (NASDAQ:ARTH) opened at 0.86 on Friday. The company’s 50 day moving average is $0.68 and its 200-day moving average is $0.59. Arch Therapeutics has a 12 month low of $0.41 and a 12 month high of $0.86. The company’s market cap is $126.44 million.
COPYRIGHT VIOLATION WARNING: “Arch Therapeutics Inc (ARTH) Lifted to Hold at ValuEngine” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/29/arch-therapeutics-inc-arth-lifted-to-hold-at-valuengine.html.
About Arch Therapeutics
Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related stocks with our FREE daily email newsletter.